Blackstone Group LP Has Boosted Pacific Biosciences Calif In (PACB) Stake by $3.42 Million

August 9, 2018 - By Richard Slagle

Pacific Biosciences of California, Inc. (NASDAQ:PACB) LogoInvestors sentiment increased to 1.93 in 2018 Q1. Its up 0.80, from 1.13 in 2017Q4. It improved, as 8 investors sold PACB shares while 19 reduced holdings. 11 funds opened positions while 41 raised stakes. 88.24 million shares or 15.71% more from 76.26 million shares in 2017Q4 were reported. Lenox Wealth Management reported 175 shares stake. Parametric Assoc Ltd Liability invested in 0% or 310,531 shares. Jpmorgan Chase And Company invested in 0% or 30,101 shares. Invesco has 58,535 shares. The Connecticut-based Verition Fund Mgmt Lc has invested 0% in Pacific Biosciences of California, Inc. (NASDAQ:PACB). Proshare Advsrs Limited Co has 0% invested in Pacific Biosciences of California, Inc. (NASDAQ:PACB) for 75,182 shares. Ing Groep Nv reported 207,997 shares or 0.01% of all its holdings. Barclays Public Limited Company reported 32,563 shares stake. California Employees Retirement Sys holds 457,400 shares. Carret Asset Limited Liability Com accumulated 0.01% or 17,000 shares. Tiedemann Advisors Ltd has 0% invested in Pacific Biosciences of California, Inc. (NASDAQ:PACB). Voya Investment Limited Liability Company has invested 0% in Pacific Biosciences of California, Inc. (NASDAQ:PACB). New York-based Blackrock has invested 0% in Pacific Biosciences of California, Inc. (NASDAQ:PACB). Ulysses Mngmt Ltd Liability reported 0.04% in Pacific Biosciences of California, Inc. (NASDAQ:PACB). Price T Rowe Associates Md reported 40,826 shares stake.

Blackstone Group Lp increased its stake in Pacific Biosciences Calif In (PACB) by 70.99% based on its latest 2018Q1 regulatory filing with the SEC. Blackstone Group Lp bought 1.71 million shares as the company’s stock declined 0.39% with the market. The institutional investor held 4.12M shares of the capital goods company at the end of 2018Q1, valued at $8.45 million, up from 2.41M at the end of the previous reported quarter. Blackstone Group Lp who had been investing in Pacific Biosciences Calif In for a number of months, seems to be bullish on the $534.37 million market cap company. The stock increased 2.02% or $0.08 during the last trading session, reaching $4.05. About 998,013 shares traded or 13.31% up from the average. Pacific Biosciences of California, Inc. (NASDAQ:PACB) has declined 32.53% since August 9, 2017 and is downtrending. It has underperformed by 45.10% the S&P500.

More notable recent Pacific Biosciences of California, Inc. (NASDAQ:PACB) news were published by: Benzinga.com which released: “The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs” on July 28, 2018, also Fool.com with their article: “Pacific Biosciences of California Revenue Up Thanks to More System Installs” published on August 03, 2018, Nasdaq.com published: “Detailed Research: Economic Perspectives on Allete, Sterling Construction, Illumina, PROS, Altra Industrial Motion …” on August 06, 2018. More interesting news about Pacific Biosciences of California, Inc. (NASDAQ:PACB) were released by: Globenewswire.com and their article: “Pacific Biosciences Appoints Christian Henry to Board of Directors” published on July 31, 2018 as well as Benzinga.com‘s news article titled: “The Daily Biotech Pulse: Denali’s Parkinson’s Candidate Clears Early-Stage Trials, Dexcom’s Strong Quarter” with publication date: August 02, 2018.

Pacific Biosciences of California, Inc. (NASDAQ:PACB) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.